Metsera

Metsera Net Margin

Delisted

Net Profit Margin of Metsera (MTSR) as of Nov 4, 2026.

Net Margin

-

Last updated:

Net Profit Margin of Metsera is 2026 - . Net Profit Margin of Metsera was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Metsera Stock analysis

What does Metsera do? Metsera Inc. is a clinical stage biopharmaceutical company based in New York City, operating in the Health Care sector with a focus on Biotechnology. The company develops next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides for treating obesity and related conditions. Utilizing its proprietary MINT peptide library, HALO half-life extension platform, and MOMENTUM oral delivery system, Metsera has a pipeline including MET-097i, MET-233i, and MET-224o, targeting various obesity treatments with differentiated approaches. Listed on 31 January 2025, the company employs 82 staff. Metsera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Metsera stock

On Eulerpool you can find the complete historical development of Net Profit Margin Metsera since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Metsera with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Metsera

All Key Metrics — Metsera